Catalyst Biosciences Receives Patents Covering its Hemostasis and Anti-Complement Programs

-- Hemostasis patents cover next-generation coagulation factors FVIIa (CB 813d) and FIX (CB 2679d/ISU304) in the United States, Europe and Korea --

-- Anti-complement patent covers novel protease technologies and proteases that target the complement cascade in the United States and Europe --

SOUTH SAN FRANCISCO, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, today announced that it has received patents issued by the U.S. Patent and Trademark Office (USPTO), the European Patent Office (EPO) and the Korean Intellectual Property Office (KIPO) covering the Company's lead hemostasis programs, next-generation coagulation Factor VIIa and Factor IX, and the Company’s anti-complement program. These patents build on the Company’s extensive portfolio that now totals 103 patents issued world-wide.

The Company’s hemostasis program is focused on creating improved treatments for hemophilia and surgical bleeding using potent, long-acting coagulation factors that promote blood clotting. The most advanced drug candidate is a Factor VIIa variant, CB 813d, being developed for patients with severe hemophilia A and B with inhibitors, which is expected to enter a pivotal trial in 2017. The next most advanced program is the Company’s next-generation Factor IX, CB 2679d/ISU304, for the treatment of severe hemophilia B patients, which is expected to enter a Phase 1/2 trial in 2016.

The Company’s anti-complement program is focused on blocking activation of the complement cascade, a series of molecular processes that plays a central role in the body’s inflammatory and immune system. The most advanced drug candidate is CB 2782, a novel protease that cleaves complement factor 3 (C3), which the Company plans to develop initially for the prevention of ischemia-reperfusion injury driven delayed graft function (DGF) following kidney transplant.

The patents recently granted are:

  1. Factor VIIa Patents: EPO Patent No. 2679678 and Korean Patent No. 10-1623602 include claims that cover the Company’s lead next generation Factor VIIa clinical candidate, CB 813d (and related molecules) which is being developed for the potential long-term, prophylactic management of hemophilia A and B inhibitor patients.
  2. Factor IX Patent: U.S. Patent No. 9,328,339 includes claims that cover the Company’s next-generation Factor IX pre-clinical candidate, CB 2679d/ISU 304, which is being developed for the potential long-term, prophylactic management of severe hemophilia B patients.
  3. Protease Technology and Anti-Complement Factor 3 (C3) Protease Patents: U.S. Patent No. 9,290,757 and U.S. Patent No. 9,359,598 include claims directed to novel proteases that cleave specific disease targets including complement factor 3 and compositions of matter covering the Company’s development candidate CB 2782, for the potential treatment of renal delayed graft function (DGF) and other ischemia reperfusion driven diseases, and lead candidates for the Company’s Dry age-related macular degeneration (AMD) program.

"These patents protect and strengthen our intellectual property position surrounding our technology, methods of use and composition of matter for several of our therapeutic protease agents,” said Nassim Usman, Ph.D., Catalyst’s President and Chief Executive Officer. “We believe that the recently granted patents represent key components of our IP estate that build on our extensive existing patent portfolio.

About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions. To date, Catalyst has focused its product development efforts in the field of hemostasis, including the treatment of hemophilia and surgical bleeding, and in the field of inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, please visit

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts, included in this press release regarding the potential uses and value of the Company’s product candidates, patents and other intellectual property and the Company’s product development plans, including plans regarding clinical trials, are forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, potential adverse effects arising from the testing or use of the Company’s products, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, risks related to the Company’s ability to protect or enforce intellectual property rights related to its product candidates, competition and other factors that affect the Company’s ability to establish collaborations on commercially reasonable terms and the Company’s ability to successfully develop and commercialize its product candidates. Other risks and uncertainties related to the Company’s business are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contacts: Investors: Fletcher Payne, CFO Catalyst Biosciences, Inc. +1.650.871.0761 Media: Denise Powell Red House Consulting, LLC +1.510.703.9491

Source:Catalyst Biosciences, Inc.